LENZ Therapeutics, Inc. financial data

Symbol
LENZ on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
445 Marine View Ave Suite 320, Del Mar, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Graphite Bio, Inc. (to 3/19/2024)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.23K % -40.1%
Debt-to-equity 22.1 % -68%
Return On Equity -98.9 % +34.1%
Return On Assets -65.6 % -168%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.5M shares -52.6%
Common Stock, Shares, Outstanding 25.8M shares -55.4%
Entity Public Float 151M USD +0.47%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 25.6M shares +1209%
Weighted Average Number of Shares Outstanding, Diluted 25.6M shares +1209%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.7M USD -55.4%
General and Administrative Expense 41M USD +24.7%
Operating Income (Loss) -138M USD -71.5%
Nonoperating Income (Expense) 13.9M USD +265%
Net Income (Loss) Attributable to Parent -124M USD -61.9%
Earnings Per Share, Basic 7.91 USD/shares +94.7%
Earnings Per Share, Diluted 7.91 USD/shares +94.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84M USD -34.6%
Cash, Cash Equivalents, and Short-term Investments 196M USD -20.5%
Assets, Current 199M USD -20.6%
Property, Plant and Equipment, Net 164K USD -99.1%
Operating Lease, Right-of-Use Asset 1.73M USD -89.1%
Other Assets, Noncurrent 1.4M USD +294%
Assets 203M USD -29.4%
Accounts Payable, Current 4.41M USD +62%
Employee-related Liabilities, Current 1.55M USD -31.6%
Accrued Liabilities, Current 4.18M USD
Liabilities, Current 8.58M USD -30%
Operating Lease, Liability, Noncurrent 1.05M USD -97.9%
Other Liabilities, Noncurrent 83K USD
Liabilities 9.72M USD -84.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -62K USD +77.1%
Retained Earnings (Accumulated Deficit) -122M USD +62%
Stockholders' Equity Attributable to Parent 193M USD
Liabilities and Equity 203M USD -29.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -87%
Net Cash Provided by (Used in) Financing Activities 171M USD +106%
Net Cash Provided by (Used in) Investing Activities 18M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 25.9M shares -55.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 165M USD +135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 84.1M USD +13.1%
Deferred Tax Assets, Valuation Allowance 67.6M USD +77.4%
Deferred Tax Assets, Gross 67.7M USD +72.3%
Operating Lease, Liability 1.48M USD -97.2%
Depreciation 2.4M USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.3M USD +30%
Lessee, Operating Lease, Liability, to be Paid 1.68M USD -98.1%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 649K USD -77.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 577K USD -93.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 227K USD -97.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 196K USD -99.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 511K USD -93.8%
Deferred Tax Assets, Operating Loss Carryforwards 30.8M USD +93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.56M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 361K USD -95.7%
Operating Lease, Payments 1.75M USD +32.5%
Additional Paid in Capital 315M USD -42.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 73 USD -93.8%
Share-based Payment Arrangement, Expense 12.8M USD +78.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%